Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo

Shinong Wang, Mark C. Wilkes, Edward B Leof, Raimund Hirschberg

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-β receptor. In the current study we show that in cultured NRK49F-renal fibroblasts (but not in tubular or mesangial cells) TGF-β similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-β addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-β-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-β-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-β-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats. - Wang, S., Wilkes, M. C., Leof, L. B., Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalFASEB Journal
Volume19
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

transforming growth factors
Transforming Growth Factors
kidneys
p21-Activated Kinases
Kidney
phosphotransferases (kinases)
Fibroblasts
fibroblasts
Chemical activation
Protein-Tyrosine Kinases
Rats
tyrosine
collagen
Phosphorylation
Collagen Type III
Collagen Type IV
Growth Factor Receptors
Imatinib Mesylate
Macrophages
Cell proliferation

Keywords

  • ECM
  • Experimental renal fibrosis
  • Renal interstitial fibrosis
  • Unilaterial ureteral obstruction

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. / Wang, Shinong; Wilkes, Mark C.; Leof, Edward B; Hirschberg, Raimund.

In: FASEB Journal, Vol. 19, No. 1, 01.2005, p. 1-11.

Research output: Contribution to journalArticle

Wang, Shinong ; Wilkes, Mark C. ; Leof, Edward B ; Hirschberg, Raimund. / Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. In: FASEB Journal. 2005 ; Vol. 19, No. 1. pp. 1-11.
@article{fd07ffe68bfc40b9925920c53770f3f7,
title = "Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo",
abstract = "Transforming growth factor-β (TGF-β) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-β receptor. In the current study we show that in cultured NRK49F-renal fibroblasts (but not in tubular or mesangial cells) TGF-β similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-β addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-β-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-β-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-β-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats. - Wang, S., Wilkes, M. C., Leof, L. B., Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo.",
keywords = "ECM, Experimental renal fibrosis, Renal interstitial fibrosis, Unilaterial ureteral obstruction",
author = "Shinong Wang and Wilkes, {Mark C.} and Leof, {Edward B} and Raimund Hirschberg",
year = "2005",
month = "1",
doi = "10.1096/fj.04-2370com",
language = "English (US)",
volume = "19",
pages = "1--11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "1",

}

TY - JOUR

T1 - Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo

AU - Wang, Shinong

AU - Wilkes, Mark C.

AU - Leof, Edward B

AU - Hirschberg, Raimund

PY - 2005/1

Y1 - 2005/1

N2 - Transforming growth factor-β (TGF-β) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-β receptor. In the current study we show that in cultured NRK49F-renal fibroblasts (but not in tubular or mesangial cells) TGF-β similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-β addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-β-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-β-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-β-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats. - Wang, S., Wilkes, M. C., Leof, L. B., Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo.

AB - Transforming growth factor-β (TGF-β) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-β receptor. In the current study we show that in cultured NRK49F-renal fibroblasts (but not in tubular or mesangial cells) TGF-β similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-β addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-β-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-β-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-β-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats. - Wang, S., Wilkes, M. C., Leof, L. B., Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo.

KW - ECM

KW - Experimental renal fibrosis

KW - Renal interstitial fibrosis

KW - Unilaterial ureteral obstruction

UR - http://www.scopus.com/inward/record.url?scp=11244292291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244292291&partnerID=8YFLogxK

U2 - 10.1096/fj.04-2370com

DO - 10.1096/fj.04-2370com

M3 - Article

C2 - 15629889

AN - SCOPUS:11244292291

VL - 19

SP - 1

EP - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 1

ER -